According to a recent LinkedIn post from Infinity Bio Inc, the company’s VP of Scientific Development, Katy Shaw-Saliba, is expected to present a poster at the upcoming Keystone Symposia on Autoimmunity & Autoinflammation. The presentation, scheduled for March 18, 2026, focuses on using novel antigen display technology to decode the antibody reactome at scale and better understand immune history.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Infinity Bio is positioning its platform at the intersection of immunology, B-cell biology, and translational research, with an emphasis on antibody profiling. For investors, participation in a high-profile scientific meeting may enhance the company’s visibility among academic and industry researchers, potentially supporting future collaborations, technology validation, and longer-term partnering or licensing opportunities.
While the post is primarily scientific and promotional in nature, it underscores the firm’s focus on developing tools that could be relevant to drug discovery, diagnostics, or precision medicine applications. If the underlying technology proves scalable and differentiated, it could strengthen Infinity Bio’s competitive position within the biotechnology tools and immunology research markets, though no immediate revenue implications are evident from this event alone.